NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $97.59 0.00 (0.00%) As of 08/21/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort Interest About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PBE alerts:Sign Up Key Stats Today's Range$97.11▼$97.8050-Day Range$84.12▼$98.2652-Week Range$67.41▼$98.32Volume5,408 shsAverage Volume12,966 shsMarket Capitalization$307.41 millionAssets Under Management$401.81 millionDividend Yield1.58%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. Read More Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.55%0.57%0.51%0.53%Other Expenses0.08%0.52%0.53%0.60%0.54%Total Expense0.58%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.77%-0.68%Net Expense0.58%0.58%0.63%0.57%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBE ETF News HeadlinesInvesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?August 19, 2026 | finance.yahoo.comXLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist?August 1, 2026 | fool.comSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing total outflows to 14 billion. At the same time, the World Gold Council recorded the highest quarterly central bank gold buying on record, with buyers taking physical delivery instead of paper shares. | Behind the Markets (Ad)VHT vs. PBE: Which Health Care ETF Is the Better Buy?July 30, 2026 | finance.yahoo.comETF Showdown: XBI vs PBE, Which Biotech Fund Wins?July 24, 2026 | 247wallst.comInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.8106June 22, 2026 | msn.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $82.15 at the beginning of 2026. Since then, PBE stock has increased by 18.8% and is now trading at $97.59. Who are Invesco Biotechnology & Genome ETF's major shareholders? Top institutional shareholders of Invesco Biotechnology & Genome ETF include Dynamic Advisor Solutions LLC (0.17%), Compass Financial Management LLC (0.01%) and Compass Financial Management LLC (0.01%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), NVIDIA (NVDA) and Bristol Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings30 Fund Statistics Assets Under Management$401.81 million Average Daily Volume$49.74 thousand Discount/Premium0.06% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest8,827 shs Miscellaneous Outstanding Shares3,150,000Beta0.70 Creation Unit10,000 Creation Fee$500.00 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report Top 10 PBE HoldingsRegeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 5.44%Amgen (NASDAQ:AMGN)Holding Weight: 5.36%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 5.23%CareDx (NASDAQ:CDNA)Holding Weight: 5.19%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.76%Biogen (NASDAQ:BIIB)Holding Weight: 4.69%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.40%United Therapeutics (NASDAQ:UTHR)Holding Weight: 3.83%Protagonist Therapeutics (NASDAQ:PTGX)Holding Weight: 3.59%Bio-Techne (NASDAQ:TECH)Holding Weight: 3.56%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
